Reboxetine--another new antidepressant.
Reboxetine (Edronax-Pharmacia & Upjohn) is a new antidepressant drug introduced last year for the acute treatment and, in patients who respond, the maintenance treatment of depression. It is marketed as a "new selective noradrenaline reuptake inhibitor" (or 'NARI'). The manufacturer claims that reboxetine "not only lifts depressed mood" but also "helps restore social interaction", with "significantly better outcome in terms of social functioning" than fluoxetine. We assess these claims and consider the place of reboxetine in therapy.
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077593:Reboxetine
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine